Key GI Journal Articles - Colorectal - Metastatic

Chemo
EGFR Inhibitor Studies
Bevacizumab Studies
Double Biologic Studies

 Chemo

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
B Chibaudel, F Maindrault-Goebel, G Lledo, L Mineur, T André, M Bennamoun, M Mabro, P Artru, E Carola, M Flesch, O Dupuis, P Colin, AK Larsen, P Afchain, C Tournigand, C Louvet, & A de Gramont
JCO. Sep 28 2009 (ahead of print); 10.1200/JCO.2009.23.4344
Journal

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
J Cassidy, S Clarke, E Diaz-Rubio, W Scheithauer, A Figer, R Wong, S Koski, M Lichinitser, T-S Yang, F Rivera, F Couture, F Sirzen, & L Saltz
JCO. Apr 20 2008; 26 (12):2006-12
Journal | Pubmed

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
A Falcone, S Ricci, I Brunetti, E Pfanner, G Allegrini, C Barbara, L Crinò, G Benedetti, W Evangelista, L Fanchini, E Cortesi, V Picone, S Vitello, S Chiara, C Granetto, G Porcile, L Fioretto, C Orlandini, M Andreuccetti, & G Masi
JCO. May 1 2007; 25(13):1670-6
Journal | Pubmed

Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment
A Grothey, D Sargent, RM Goldberg, & HJ Schmoll
JCO. Apr 1 2004; 22(7):1209-14
Journal | Pubmed

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem, PM Hoff, P Harper, RM Bukowski, D Cunningham, P Dufour, U Graeven, J Lokich, S Madajewicz, JA Maroun, JL Marshall, EP Mitchell, G Perez-Manga, P Rougier, W Schmiegel, J Schoelmerich, A Sobrero, RL Schilsky
Br J Cancer. Mar 22 2004; 90(6):1190-7
Journal | Pubmed

A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
RM Goldberg, DJ Sargent, RF Morton, CS Fuchs, RK Ramanathan, SK Williamson, BP Findlay, HC Pitot, & SR Alberts
JCO. Jan 1 2004; 22(1):23-30
Journal | Pubmed

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, E Quinaux, C Couteau, M Buyse, G Ganem, B Landi, P Colin, C Louvet, & A de Gramont
JCO. Jan 15 2004; 22(2):229-37
Journal | Pubmed

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
ML Rothenberg, AM Oza, RH Bigelow, JD Berlin, JL Marshall, RK Ramanathan, LL Hart, S Gupta, CA Garay, BG Burger, N Le Bail, & DG Haller
JCO. Jun 1 2003; 21(11):2059-69
Journal | Pubmed

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
LB Saltz, JV Cox, C Blanke, LS Rosen, L Fehrenbacher, MJ Moore, JA Maroun, SP Ackland, PK Locker, N Pirotta, GL Elfring, & LL Miller; The Irinotecan Study Group
NEJM. Sep 28 2000; 343(13):905-14
Journal | Pubmed

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard, D Cunningham, A Roth, M Navarro, R James, P Karasek, P Jandik, T Iveson, J Carmichael, M Alakl, G Gruia, L Awad, & P Rougier
Lancet. Mar 25 2000; 355(9209):1041-7
Journal | Pubmed

Back to Top

 EGFR Inhibitor Studies

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
E Van Cutsem, C Köhne, E Hitre, J Zaluski, C Chang Chien, A Makhson, G D'Haens, T Pintér, R Lim, G Bodoky, J Kyung Roh, G Folprecht, P Ruff, C Stroh, S Tejpar, M Schlichting, J Nippgen, & P Rougier
NEJM. Apr 02 2009; 360(14):1408-17
Journal

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer *New*
CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, NC Tebbutt, RJ Simes, H Chalchal, JD Shapiro, S Robitaille, TJ Price, L Shepherd, H-J Au, C Langer, MJ Moore & JR Zalcberg
NEJM. Oct 23 2008; 359(17):1757-65
Journal

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer *New*
RG Amado, M Wolf, M Peeters, E Van Cutsem, S Siena, DJ Freeman, T Juan, R Sikorski, S Suggs, R Radinsky, SD Patterson & DD Chang
JCO. Apr 01 2008; 26(10):1626-34
Journal

Cetuximab for the Treatment of Colorectal Cancer
DJ Jonker, CJ O’Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, SR Berry,M Krahn, T Price, RJ Simes, NC Tebbutt, G van Hazel, R Wierzbicki, C Langer, & MJ Moore
NEJM. Nov 15 2007; 357(20):2040-8
Journal | Pubmed

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, JL Canon, JL Van Laethem, J Maurel, G Richardson, M Wolf, & RG Amado
JCO. May 1 2007; 25(13):1658-64
Journal | Pubmed

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, D Bets, M Mueser, A Harstrick, C Verslype, I Chau, & E Van Cutsem
NEJM. Jul 22 2004; 351(4):337-45
Journal | Pubmed

Back to Top

 Bevacizumab Studies

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study **New**
NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, GA van Hazel, B Robinson, A Broad, V Ganju, SP Ackland, G Forgeson, D Cunningham, MP Saunders, MR Stockler, Y Chua, JR Zalcberg, RJ Simes, & TJ Price
JCO. Jul 1 2010; 28(19):3191-98
Journal

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, F de Braud, S Donea, H Ludwig, G Schuch, C Stroh, AH Loos, A Zubel, & P Koralewski
JCO. Feb 10 2009; 27(5):663-671
Journal

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
LB Saltz, S Clarke, E Diaz-Rubio, W Scheithauer, A Figer, R Wong, S Koski, M Lichinitser, T-S Yang, F Rivera, F Couture, F Sirzen, & J Cassidy
JCO. Apr 20 2008; 26(12):2013-9
Journal | Pubmed

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
BJ Giantonio, PJ Catalano, NJ Meropol, PJ O'Dwyer, EP Mitchell, SR Alberts, MA Schwartz, & AB Benson III
JCO. Apr 20 2007; 25(12):1539-44
Journal | Pubmed

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
FF Kabbinavar, J Hambleton, RD Mass, HI Hurwitz, E Bergsland, & S Sarkar
JCO. Jun 1 2005; 23(16):3706-12
Journal | Pubmed

Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
HI Hurwitz, L Fehrenbacher, JD Hainsworth, W Heim, J Berlin, E Holmgren, J Hambleton, WF Novotny, & F Kabbinavar
JCO. May 20 2005; 23(15):3502-8
Journal | Pubmed

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J Hainsworth, W Heim, J Berlin, A Baron, S Griffing, E Holmgren, N Ferrara, G Fyfe, B Rogers, R Ross, & F Kabbinavar
NEJM. Jun 3 2004; 350(23):2335-42
Journal | Pubmed

Back to Top

 Double Biologic Studies

 A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J Hecht, E Mitchell, T Chidiac, C Scroggin, C Hagenstad, D Spigel, J Marshall, A Cohn, D McCollum, P Stella, R Deeter, S Shahin, & RG Amado
JCO. Feb 10 2009; 27(5):1408-17
Journal

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
J Tol, M Koopman, A Cats, CJ Rodenburg, G Creemers, JG Schrama, F Erdkamp, AH Vos, CJ van Groeningen, H Sinnige, DJ Richel, EE Voest, JR Dijkstra, ME Vink-Börger, NF Antonini, L Mol, J van Krieken, O Dalesio, & C Punt
NEJM. Feb 05 2009; 360(6):563-72
Journal

Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
L Saltz, H Lenz, H Kindler, H Hochster, S Wadler, P Hoff, N Kemeny, E Hollywood, M Gonen, M Quinones, M Morse, & H Chen
JCO. Oct 10 2007; 25 (29):4557-61
Journal | Pubmed

Back to Top